/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Tejon Ranch Co. Decries False and Misleading Campaign Organized by Opponents to Recently-Approved Centennial Master Planned Development
Demands extremist groups remove knowingly false, inaccurate and
misleading material and video from websites
TEJON RANCH, Calif.–(BUSINESS WIRE)–Tejon Ranch Co. demands that the California Native Plant Society (CNPS)
remove material, including a video, from an anti-Centennial website
which Tejon Ranch believes contains recklessly, if not knowingly false,
inaccurate and misleading material. California Native Plant Society has
partnered with the Tucson, Arizona-based Center for Biological Diversity
(CBD), a longtime litigant against Tejon Ranch projects, in opposition
to Centennial and this latest action to mischaracterize Centennial is
true to form for both groups.
“90% of Tejon Ranch—240,000 acres—will be permanently conserved.
Amazingly, that is not enough for some extremist groups,” said Michael
R.W. Houston, Tejon Ranch Co.’s General Counsel. “We call upon them to
cease and desist their campaign of presenting false, inaccurate and
misleading statements to the public in an effort to undermine Los
Angeles County’s recent approval of Centennial, as well as their efforts
to damage the overall Tejon Ranch Conservation and Land Use Agreement,
which is supported by major respected conservation groups like Audubon
California, the Natural Resources Defense Council, the Sierra Club,
Endangered Habitats League, and others.”
The video falsely accuses shareholders of Tejon Ranch Co. of engaging in
unlawful activity. Here is a portion of the text from the video:
The Tejon Ranch Corporation is a Wall Street traded company owned
primarily by a large group of Hedge Fund looters
The video summary claims the building of Centennial would destroy 6,000
acres of wildflower habitat, leaving the impression that all the
landscapes shown in the video are from the Centennial site. This is not
accurate.
California Native Plant Society
Published on May
1, 2019
Photographer Richard Dickey captures the magnificent beauty of Tejon
Ranch, where LA County has just approved a new city of 55,000. More than
6,000 acres of wildflower habitat will be destroyed.
In fact, most of the landscapes shown in the video are not from, or
do not show the Centennial planning area, and a significant percentage
of the land depicted in the video is not even part of Tejon Ranch.
Given that the author of the web-article in which the video appears
claims to have spent over “200 days on Tejon Ranch”, and the
photographer/producer of the video claims to have spent 30 years
photographing the area, it is appalling that both the author and video
producer would so recklessly insinuate, if not blatantly assert, that
the land shown is located either on Tejon or in the Centennial project
area – when much of it is not.
Depicting locations that are either not on Tejon Ranch or not located
in the Centennial project, while representing such sites are located in
those locales, is false, severely misleading and fraudulent. This
sort of deceptive activity is consistent with CBD’s past practices.
CBD used a similar tactic against Arizona rancher Jim Chilton when it
posted knowingly false and misleading pictures of his ranching lease on
its website back in 2002. Chilton successfully sued for defamation and
was awarded $600,000 by a jury, which included punitive damages. The
case shows the lengths CBD will go to in pursuit of its radical agenda.
They clearly do not feel constrained by the truth, even asserting to the
Arizona appellate court in Mr. Chilton’s case that they had a First
Amendment right to lie, an argument the court rightfully rejected as it
affirmed the jury’s verdict and damage award.
In addition to having a history of using false and misleading
information to damage those they oppose, CBD appears to spend most of
its time and its substantial resources on litigation, all designed, in
the words of CBD co-founder Kieran Suckling, ”to create severe economic
pain.“ CBD has consistently and continually sued proposed housing
developments in California, which does nothing to help, and actually
exacerbates the housing crisis in California. Given its agenda to
oppose, delay and obstruct, it’s clear that the “economic pain” CBD
wants to inflict is being felt by young and middle-class Californians
who find decent housing to be unavailable and unaffordable.
Approved by the Los Angeles County Board of Supervisors on April 30,
2019, Centennial addresses the serious need to provide additional
housing that’s within reach of middle-class families in Southern
California. Centennial also creates a new job center for Los Angeles
County as it gives companies the opportunity to locate in an area where
their employees could afford to live. Centennial is expected to create
23,000 permanent jobs on site and nearly 25,000 construction jobs, with
at least 30% of those jobs going to local residents. Centennial will
offer price attainable homes and 18% of the housing units will be
officially designated affordable units. With Governor Newsom proposing
to build more than 400,000 homes a year, Centennial can be part of the
solution to the housing crisis in California. All while still conserving
90% of Tejon Ranch.
CBD has initiated seven different legal challenges against Tejon Ranch
over the last 16 years in both state and federal court. It should
therefore come as no surprise that its representatives recently promised
to sue Los Angeles County over its approval of Centennial. Given that
CBD sued and lost, both at the superior and appellate court level, when
it challenged Los Angeles County over its approval of the Antelope
Valley Area Plan– which designated the site where Centennial is located
for future development, it would be simply rehashing issues on which
it’s already sued and lost. It’s no wonder CBD has been called nothing
more than a lawsuit-factory, spending much of its time and resources
either in court or issuing press releases, rather than engaging in
proactive conservation.
CBD had the opportunity to engage in proactive conservation on Tejon
Ranch. It was initially involved in negotiations, along with respected
environmental organizations such as the Sierra Club, Natural Resources
Defense Council, Audubon California, Endangered Habitats League, and
others, that led to the historic and science-based Tejon Ranch
Conservation and Land Use Agreement, in which 90% of Tejon Ranch will be
conserved. This agreement was supported by two previous Governors’
Administrations, and because of this agreement, Tejon Ranch can play a
vital role in the building of residential units to help meet Governor
Newsom’s housing goals for California, all while conserving 240,000
acres in perpetuity.
Even though published reports indicate it was CBD representatives
themselves who advocated for and demanded the 90/10 ratio of
conservation to development, the organization walked away from the
negotiations just months before an agreement was reached. CBD is
recently quoted in a different publication saying it preferred to retain
the right to sue (and presumably collect attorneys fees) than
compromise, even if that compromise would result in a guaranteed
positive conservation outcome.
If it does sue—again—over Centennial, it’s likely to hypocritically
raise the issue of wildfires, as it did in a recently-filed lawsuit
against another housing development in Los Angeles County. In another
instance of what clearly appears to be CBD taking whatever position best
suits them, even if it’s contradictory to other positions it’s taken,
CBD opposed Governor Newsom’s emergency declaration streamlining 35
wildfire mitigation projects that would help protect 2.2 million
Californians in over 200 communities from future wildfires, claiming it
would undercut environmental protections. In that instance, CBD said the
best measure to protect homes against wildfire wouldn’t be to thin
forests and remove dead and dying brush from nearby at-risk communities,
but to retrofit houses to current building standards and create
defensible space around them, something that clearly could not be
accomplished before the next wildfire season.
But the prescription that CBD claims is the best defense against
wildfire is exactly what the plan for Centennial requires. Though, at
Centennial, instead of needing to retrofit homes, houses and other
buildings will be constructed from the very beginning based on the most
stringent fire codes and building standards in place at the time. These
plans have been reviewed and approved by all appropriate State and
County Fire authorities. The defensible space standards at Centennial
also far exceed state requirements.
Tejon Ranch Co. calls upon CBD and CNPS to cease their false and
misleading campaign against Centennial, to support the Ranchwide
Agreement that permanently conserves 90% of Tejon Ranch, to respect the
overwhelming community and state support it received, and to recognize
the deleterious impact of their positions on the urgent need to produce
more housing for thousands of families in California.
Contacts
Barry Zoeller, Vice President, Corporate Communications & Investor
Relations
(661) 663-4212
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Innocan
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].
Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.
Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.“
Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:
“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market
[2] https://www.cdc.gov/opioids/data/index.html
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html
Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom
NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.
Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.
“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”
The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.
Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks agoAvicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
transfer1 week agoIMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis6 days ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis5 days ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
CCELL®1 week agoCCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
